[go: up one dir, main page]

EA200000146A1 - Лиганды, включая антитела, проявляющие реактивность в отношении эндокринных клеток - Google Patents

Лиганды, включая антитела, проявляющие реактивность в отношении эндокринных клеток

Info

Publication number
EA200000146A1
EA200000146A1 EA200000146A EA200000146A EA200000146A1 EA 200000146 A1 EA200000146 A1 EA 200000146A1 EA 200000146 A EA200000146 A EA 200000146A EA 200000146 A EA200000146 A EA 200000146A EA 200000146 A1 EA200000146 A1 EA 200000146A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
ligands
endocrine cells
including antibodies
reactivity against
Prior art date
Application number
EA200000146A
Other languages
English (en)
Other versions
EA003131B1 (ru
Inventor
Арпи Матоссиан-Роджерс
Original Assignee
Арпи Матоссиан-Роджерс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Арпи Матоссиан-Роджерс filed Critical Арпи Матоссиан-Роджерс
Publication of EA200000146A1 publication Critical patent/EA200000146A1/ru
Publication of EA003131B1 publication Critical patent/EA003131B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

Настоящее изобретение представляет моноклональные и поликлональные антитела, распознающие молекулы на секреторных клетках различных тканей, являющихся мишенями аутоиммунных заболеваний, обеспечивающих унификацию способа профилактики и лечения аутоиммунных заболеваний и других состояний, в которые вовлечены нарушения гормональной регуляции, гиперинсулинемия и инсулиновая невосприимчивость. Также представляется способ выявления сходных антител в сыворотке человека или других жидкостях тела, которые могут быть использованы в диагностических наборах реактивов. Способы лечения, вытекающие из настоящего изобретения, включают введение препаратов антител, их молекул-мишеней и векторов, включающих последовательности, кодирующие эти антитела и их молекулы-мишени.Отчет о международном поиске был опубликован 1999.06.10.
EA200000146A 1997-07-21 1998-07-20 Лиганды, включая антитела, проявляющие реактивность в отношении эндокринных клеток EA003131B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)

Publications (2)

Publication Number Publication Date
EA200000146A1 true EA200000146A1 (ru) 2000-10-30
EA003131B1 EA003131B1 (ru) 2003-02-27

Family

ID=26311906

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000146A EA003131B1 (ru) 1997-07-21 1998-07-20 Лиганды, включая антитела, проявляющие реактивность в отношении эндокринных клеток

Country Status (21)

Country Link
US (2) US6689359B1 (ru)
EP (2) EP1595951A1 (ru)
JP (1) JP2002511765A (ru)
KR (2) KR100567277B1 (ru)
CN (1) CN1330754C (ru)
AT (1) ATE297983T1 (ru)
AU (1) AU758455B2 (ru)
BR (1) BR9810118A (ru)
CA (1) CA2296842C (ru)
CU (1) CU23412A3 (ru)
DE (1) DE69830588T2 (ru)
DK (1) DK0998556T3 (ru)
EA (1) EA003131B1 (ru)
ES (1) ES2245034T3 (ru)
IL (3) IL133277A0 (ru)
NZ (1) NZ501424A (ru)
PL (1) PL204503B1 (ru)
PT (1) PT998556E (ru)
SI (1) SI0998556T1 (ru)
TR (1) TR200000181T2 (ru)
WO (1) WO1999005175A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385879A1 (en) * 1999-09-23 2001-03-29 Rigel Pharmaceuticals, Inc. Traf4 associated cell cycle proteins, compositions and methods of use
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EA015629B1 (ru) * 2005-08-11 2011-10-31 Арпи Матоссиан-Роджерс Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US9217172B2 (en) * 2011-09-29 2015-12-22 Cellsnap, Llc Compositions and methods for toxigenicity testing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ イミューン レスポンス コーポレイション 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
KR20010022063A (ko) 2001-03-15
CA2296842C (en) 2012-03-20
WO1999005175A3 (en) 1999-06-10
CA2296842A1 (en) 1999-02-04
KR100670070B1 (ko) 2007-01-19
PL204503B1 (pl) 2010-01-29
EP1595951A1 (en) 2005-11-16
IL133277A0 (en) 2001-04-30
AU8451798A (en) 1999-02-16
US6689359B1 (en) 2004-02-10
SI0998556T1 (en) 2005-10-31
IL176076A0 (en) 2006-10-05
DE69830588D1 (de) 2005-07-21
DK0998556T3 (da) 2005-10-17
US20050100541A1 (en) 2005-05-12
KR100567277B1 (ko) 2006-04-05
TR200000181T2 (tr) 2000-05-22
CN1264426A (zh) 2000-08-23
KR20050046825A (ko) 2005-05-18
EA003131B1 (ru) 2003-02-27
WO1999005175A2 (en) 1999-02-04
ATE297983T1 (de) 2005-07-15
DE69830588T2 (de) 2006-05-04
PT998556E (pt) 2005-09-30
IL133277A (en) 2006-09-05
IL176076A (en) 2010-06-16
ES2245034T3 (es) 2005-12-16
BR9810118A (pt) 2000-08-08
CN1330754C (zh) 2007-08-08
EP0998556B1 (en) 2005-06-15
CU23412A3 (es) 2009-09-08
EP0998556A2 (en) 2000-05-10
PL338449A1 (en) 2000-11-06
NZ501424A (en) 2005-08-26
JP2002511765A (ja) 2002-04-16
AU758455B2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DK1307564T3 (da) Forbindelser og fremgangsmåde til behandling og diagnose af chlamydiainfektion
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
EP1408333A3 (en) Diagnosis and treatment of Alzheimer's disease
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2002034282A3 (en) Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
GB9715177D0 (en) Medicament
AU2003215667A1 (en) Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof
WO2004020666A3 (en) Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
EP1821104A3 (en) Method for diagnosing efficacy of xenotypic antibody therapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY RU